Michael D. Banov, M.D. - Curriculum Vitae
BOARD CERTIFICATION
American Board of Psychiatry and Neurology-Re-certification September 2006
American Board of Psychiatry and Neurology-February 1995
American Board of Adolescent Psychiatry-June 1997
Certification in Addiction Psychiatry by American Board of Psychiatry and Neurology- July 1998
RESEARCH CERTIFICATION
Certified Clinical Research Investigator (CCRI). Certification by Association of Clinical Research Professionals (ACRP), 2002-2008
OFFICE ADDRESS
Northwest Behavioral Medicine and Northwest Behavioral Research Center
108 Margaret Avenue
Marietta, GA 30060
(770) 422-2009
Northwest Behavioral Medicine and Northwest Behavioral Research Center
11755 Pointe Place, Suite A-1
Roswell, GA 30076
(770) 667-1264
CURRENT POSITION
Medical Director, Northwest Behavioral Medicine
Adolescent, Adult, and Geriatric Psychiatry - March 1994 to present
Marietta and Roswell, GA
Medical Director, Northwest Behavioral Research Center
Marietta, GA-March 1996 to present
Medical Director and President, Psychsource LLC- A not-for-profit organization committed to providing mental health resource information to the community.
Alpharetta, GA-June 1999 to present
Physician Advisory Board-Skyland Trail Mental Health Treatment Center
Atlanta, GA- 2003-present
HOSPITAL AFFILIATIONS
Kennestone Hospital - June 1994 to present
Marietta, GA
Ridgeview Institute - March 1994 to present
Smyrna, GA
Brawner North Hospital. - March 1994 to June 1996
Smyrna, GA
Northside Hospital- June 1995 to June 1996
Atlanta, GA
Charter-Peachford Hospital- June 1995-June 2002
Atlanta, GA
POSITIONS HELD
Chief, Department of Psychiatry-August 1997-June 1999
Kennestone Hospital, Marietta, GA
Director of Medical Education, Ridgeview Institute- March 1994 to October 1998
Atlanta, GA
Clinical Instructor in Psychiatry - July 1993 to December 1993
Harvard Medical School, Boston, MA
Assistant Attending Psychiatrist - July 1993 to December 1993
McLean Hospital, Belmont, MA
POSTGRADUATE TRAINING
Chief Resident, Psychotic Disorders Program, McLean Hospital, Consolidated Department of Psychiatry, Harvard Medical School - 1992 to 1993
Consultation-Liaison Service, Massachusetts General Hospital, Boston, MA - 1992
Clinical Fellow in Adult Psychiatry, McLean Hospital, Consolidated Department of Psychiatry, Harvard Medical School - 1990 to 1993
Medical Internship in Internal Medicine, The University Hospital, Boston University Medical Center - 1989 to 1990
EDUCATION
M.D. Emory University School of Medicine, Atlanta, GA - 1986 to 1989
Medical University of South Carolina, Charleston, SC - 1985 to 1986
A.B. Duke University, Durham, NC - Religion - 1984
Tel Aviv University, Tel Aviv, Israel - 1980
HONORS
The Dr. Henry P&M Page Durkee Laughlin Fellowship Award - 1993
Harry C. and Maida Solomon Award for most outstanding research, Harvard Medical School Consolidated Department of Psychiatry - 1993
Letter of academic achievement, Medical University of South Carolina - 1986
Magna Cum Laude, Duke University - 1984
Class Honors, Dean's List, Duke University - 1981 to 1982
PROFESSIONAL EXPERIENCE
Psychiatric Consultant/Doctor on Call - 1991 to 1993
Human Resource Institute, Boston, MA
Carney Hospital, Boston, MA
Norwood Hospital, Norwood, MA
Waltham-Weston Hospital, Waltham, MA
Psychopharmacology Consultant to geriatric services and day program for chronically mentally ill patients, Tri-City Mental Health and Retardation Center, Everett, MA - 1992 to 1993
LICENSURE
Georgia Composite State Board of Medical Examiners-1994 to present. License No. 037945
Commonwealth of Massachusetts Board of Registration in Medicine-1990 to 1996
Diplomate of National Board of Medical Examiners-1990
PROFESSIONAL ACTIVITIES
Lawyer Assistance Committee, State Bar of Georgia-August 2004-present
Georgia Psychiatric Physicians Association, Economic Affairs Committee-August 2004-present
Credentialing Committee, Kennestone Hospital-August 1997-June 2001
Utilization Review Committee, Kennestone Hospital- June 1995-June 2001
Chairman, Continuing Medical Education, Ridgeview Institute-March 1995-October 1998
Outcomes Research Committee, Ridgeview Institute- March 1995-October 1998
Drug Evaluation Committee, Ridgeview Institute- March 1995-August 1997
Economic Affairs Committee, Georgia Psychiatric Physicians Association-February 1994 to June 1996
Medical Records Committee, Brawner Hospital-May 1994-June 1996
Secretary-Treasurer, McLean Residents' Association - 1990 to 1993
McLean Psychopharmacology Journal Club - 1990 to 1993
President, Super Health 2000 - An organization of over 100 health professionals who educate school and community groups on 15 health topics - 1985 to 1986
PUBLICATIONS
Banov MD, Kulick, AR, Oepen G, Pope HG. A New Identity for Misidentification Syndromes. Compr Psychiatry, 1993; 34:114-117.
Banov MD, Tohen M, Friedberg J. High Risk of Eosinophilia in Women Treated with Clozapine. J Clin Psychiatry, 1993; 54:466-69.
Banov MD, Zarate CA, Scialabba D, Tohen M, Wines JD, Kolbrener M, Kim JW, Cole JO. Clozapine Therapy in Refractory Affective Disorders: Polarity Predicts Response in Long-Term Follow-Up. J Clin Psychiatry, 1994; 55:295-300.
Sachs GS, Lafer B, Stoll AL, Banov MD, Thibault AB, Tohen M, Rosenbaum JF. A Double- Blind Trial of Bupropion Versus Desipramine for Bipolar Depression. J Clin Psychiatry, 1994; 55:391-93.
Banov MD. Stay Tuned:Recognizing and Treating Attention Deficit Hyperactivity Disorder in Adults. Insight, 1994; 15:28-31.
Stoll AL, Banov MD, Kolbrener M, Mayer PV, Tohen M, Strakowski A, Castillo J, Suppes P, Cohen BM. Neurological Factors Predict a Favorable Valproate Response in Bipolar Disorder. J Clin Psychopharmacology, 1994; 14(5):311-3
Banov, MD. Brain Medicines: Recent Developments in Psychopharmacology. Insight, 1995; 16:24-7.
Zarate CA, Tohen M, Banov MD, Weiss MK, Cole JO. Is Clozapine a Mood Stabilizer? J Clin Psychiatry, 1995; 56:108-112.
Pillay SS, Stoll AL, Weiss MK, Tohen M, Zarate CA, Banov MD, Cole JO. EEG Abnormalities Before Clozapine Therapy Predict a Good Clinical Response to Clozapine. Ann Clin Psychiatry, 1996; 8(1):1-5.
Banov MD. Again & Again: Treatment Strategies for Obsessive-Compulsive Spectrum Disorders. Insight, 1997;18:26-9.
Banov MD. Improved Outcome in Fluvoxamine Treated Patients With SSRI-Induced Sexual Dysfunction. J Clin Psychiatry, 1999; 60(12): 866-868
Green, AI, Tohen, M, Patel, JK, et al. Clozapine in the Treatment of Refractory Psychotic Mania. Am J Psychiatry, 2000; 157(6): 982-986.
Tohen M, Jacobs TG, Grundy SL, Banov MC, McElroy SL, Janica PG, Zhang F, Toma V, Francis J, Sanger T, Tollefson GD, Breier A: Efficacy of olanzapine in acute bipolar mania: a double-blind, placebo-controlled study. Arch Gen Psychiatry 2000; 57:841-849
Mauricio Tohen, Joseph R. Calabrese, Gary S. Sachs, Michael D. Banov, Holland C. Detke, Richard Risser, Robert W. Baker, James C.-Y. Chou, and Charles L. Bowden
Randomized, Placebo-Controlled Trial of Olanzapine as Maintenance Therapy in Patients With Bipolar I Disorder Responding to Acute Treatment With Olanzapine Am J Psychiatry 2006 163: 247-256
SUBMITTED PUBLICATIONS
Banov MD, Zarate CA, Cohen DM, Frankenburg F, Scialabba D, Kolbrener M, Wines JD, Choras P, Tohen M. Successful Long-Term Use of Clozapine in Refractory Psychotic Disorders with Co-morbid Substance Abuse.
CLINICAL PSYCHOPHARMACOLOGY RESEARCH
Principal Investigator:
A Phase IIIB, randomized, double-blind, multicenter, parallel-group, placebo-controlled, dose optimization study, designed to evaluate the efficacy and safety of XXX in adolescents aged 13-17 years with Attention-Deficit/Hyperactivity Disorder (ADHD), October 2007- present.
A Phase IIIB, long-term, open-label, multicenter, extension study designed to evaluate the safety and efficacy of XXX in adolescents aged 13-17 years with Attention-Deficit/Hyperactivity Disorder (ADHD), October 2007-present.
An open-label trial measuring satisfaction and convenience of two formulations of XXX in subjects with a mood disorder. October 2007-March 2008.
A Phase III, Randomized, Double-blind, Multi-center, Placebo-controlled, Parallel-group, Forced Dose Titration, Safety and Efficacy Study of XXX in Adults with Attention-Deficit Hyperactivity Disorder (ADHD). March 2005-November 2007.
XXX Combination Versus XXX in the Treatment of Bipolar I Depression. March 2005-July 2007.
An 8-Week, Open-Label Study to Characterize the Response to XXX Treatment at Dosages up to XXX in Children and Adolescents With Attention-Deficit/Hyperactivity Disorder With an Open-Ended Extension Period, November 2005-February 2007.
A Multi-center, Double-blind, Randomized-withdrawal, Parallel-group, Placebo-controlled Phase III Study of the Efficacy and Safety of XXX as Monotherapy in the Maintenance Treatment of Patients with Major Depressive Disorder Following an Open-Label Stabilisation Period, March 2006-August 2007.
A Multicenter, Double-Blind, Randomized, Parallel-Group, Placebo-Controlled Phase III Study of the Efficacy and Safety of XXX as Monotherapy in the Treatment of Adult Patients with Major Depressive Disorder, April 2006-August 2007.
A Six-Week, Double-Blind, Multicenter, Placebo-Controlled Study Evaluating the Efficacy and Safety of Flexible Doses of XXX in Outpatients with Bipolar I Depression, February 2006-June 2007.
Efficacy, Safety, and Tolerability of XXX in the Treatment of Children aged 6-17 years With ADHD-associated Insomnia. A Multicenter, Randomized, Double-Blind, Placebo-Controlled Study. March 2006-September 2006.
A randomized, double-blind, placebo-controlled, multi-center study of XXX in patients with opioid dependence. November 2006-present.
A multi-center, double-blind, randomized, parallel-group, placebo-controlled Phase III study of the efficacy and safety of XXX SR as mono-therapy in the treatment of elderly patients with MDD, March 2007-present.
A multi-center, double-blind, randomized, parallel-group, placebo-controlled Phase III study of the efficacy and safety of XXX SR as mono-therapy in the treatment of elderly patients with GAD, March 2007-present.
A multicenter, randomized, 8-week double-blind acute phase followed by a 6-month continuation phase (open-label or double-blind) study to evaluate the efficacy, safety, and tolerability of XXX verses XXX in postmenopausal women with major depressive disorder. January 2007-present.
A long-term, open-label, and single arm study of XXX 30mg, 50mg, or 70mg per day in adults with Attention Deficit Hyperactivity Disorder. July 2006-March 2008.
A 2-year, Prospective, Blinded-Rater, Open-Label, Active-Controlled, Multi-Center, Randomized Study of Long-Term Efficacy and Effectiveness Comparing XXX and XXX in Adults with Schizophrenia. May 2006-present.
A Comparison of XXX Extended-Release VS. Placebo in the Treatment of Insomnia Associated With Generalized Anxiety Disorder (GAD) When Used Concomitantly With XXX. March 2006 to January 2008.
A Multicenter, Randomized, Parallel-group, Double-blind, Phase III Comparison of the Efficacy and Safety of XXX to Placebo When Used as Adjunct to Mood Stabilizers (XXX or XXX) in the Maintenance Treatment of bipolar I Disorder in Adult Patients. February 2004 to February 2007.
A Randomized, Double-Blind, Placebo Controlled, Multicenter Study To Evaluate The Efficacy, Safety, And Tolerability Of XXX In Patients With Generalized Anxiety. Start September 2005 to present.
A multi-center, double-blind, randomized-withdrawal, parallel-group, placebo-controlled Phase III study of the efficacy and safety of XXX as monotherapy in the maintenance treatment of patients with Generalized Anxiety Disorder following an open-label stabilization period. November 2006-August 2007.
A multi-center, double-blind, randomized, parallel-group, placebo-controlled phase III study of the efficacy and safety of XXX in combination with an antidepressant in the treatment of patients with major depressive disorder with inadequate response to an antidepressant treatment. November 2006-August 2007.
A Phase III, Randomized, Double-blind, Multi-center, placebo-controlled, parallel-group, forced dose titration, safety, and efficacy study of XXX in adults with Attention Deficit Hyperactivity Disorder. May 2006-Dec 2006.
An Eight-Week, Multinational, Multicenter, Randomized Double-blind, Placebo-controlled study, with XXXX as an Active Control to Evaluate the Efficacy, Safety and Tolerability of XXXX 100 mg in Elderly Patients with Major Depressive Disorder March 2007 to November 2007.
A Randomized Comparison of Outcomes in Patients with Treatment Resistant Depression who receive XXX therapy Administered at Different Amounts of Electrical Charge. August 2007 to Present.
A Randomized, Double-blind, Placebo Controlled Parallel Group Study to Evaluate the Safety and Efficacy of XXXX in Patients with Recurrent Major Depressive Disorder. July 2007 to July 2008.
A Multi-Center, Randomized, Double-Blind, Parallel-Group Fixed dose study of the Effect on Weight of XXXX versus XXXX in the Treatment of Outpatient with Schizophrenia. September 2006 to present.
An 8 week Randomized Double-Blind Fixed Dose, Placebo-Controlled Parallel Group, Multicenter Study of the Efficacy, Safety and Tolerability of XXXX 25mg and 50 mg in the treatment of Major Depressive Disorder with an Open Label Extension. December 2006 to present.
An 8 week Randomized, Double blind, fixed dose, Placebo-Controlled, Parallel Group, Multi-Center Study of the Efficacy, Safety and Tolerability of XXX in the treatment of Insomnia Associated with Newly Diagnosed Major Depressive Disorder. February 2006 to July 2007.
A Phase II randomized double blind placebo controlled study to evaluate the Efficacy of XXXX in the treatment of Insomnia. March 2006 to December 2006.
A Multicenter, Randomized, Double Blind, Placebo Controlled Study of XXX in the Treatment of Patients with Bipolar I Disorder with Major Depressive Episode, June 2005-July 2006.
A 9-Week, Randomized, Double-Blind, Placebo-Controlled, Parallel Study of 500 Inpatients and Outpatients Meeting Diagnostic Criteria For a Mild to Moderate Manic or Mixed Episodes Associated with Bipolar I Disorder. October 2004 to March 2006.
A Randomized, Double-Blind, Placebo Controlled Multicenter Study to Evaluate the Efficacy, Safety, and Tolerability of XXX in Patients with Generalized Anxiety Disorder August 2005-present.
A Randomized Double-Blind Parallel Group Placebo-Controlled Fixed Dose Study Evaluating the Efficacy and Safety of XXX in Subjects with Major Depressive Disorder. September 2004-October 2005.
A Multicenter, Double-Blind, Placebo-Controlled, Fixed- Dose, 8 week Evaluation of the Efficacy and Safety of XXX in the Treatment of Bipolar Disorder Patients Currently Experiencing a Major Depressive Episode. September 2004- October 2005.
A Multicenter, Double-Blind, Placebo-Controlled, Fixed- Dose, 8 week Evaluation of the Efficacy and Safety of XXX in the Treatment of Major Depression in Patients with Type II Bipolar Disorder. February 2003- October 2005.
A Multicenter, Randomized, Parallel-group, Double-Blind, Phase III Comparison of the Efficacy and Safety of XXX When Used as Adjunct to Mood Stabilizers in the Maintenance Treatment of Bipolar I Disorder in Adult Patients. March 2004-August 2005.
A Phase III, Randomized, Double Blind, Multicenter, Placebo Controlled, Parallel-Group, Forced Dose Titration, Safety and Efficacy Study of XXX in Adults with Attention Deficit Hyperactivity Disorder June 2005-September 2005
XXX verses XXX and Placebo in the Treatment of Mild to Moderate Mania Associated with Bipolar Disorder October 2004- November 2005.
XXX verses XXX in the Treatment of Bipolar I Disorder October 2003-October 2005.
An 8-Week, Randomized, Double-Blind, Parallel-Group, Placebo-Controlled, Multicenter, Fixed Dose Study Comparing the Efficacy and Safety of XXX or XXX to Placebo in Moderately to Severely Depressed Patients with Major Depressive Disorder. September 2002 to June 2003.
A Study of XXX plus XXX in Combination for Treatment-Resistant Depression without Psychotic Features. February 2002 to September 2005.
An Eight-week, Double-Blind, Placebo-Controlled, Multicenter Study to Evaluate the Safety and Efficacy of 2 Doses of XXX and XXX in Subjects with Major Depressive Disorder. October 2001 to November 2002.
A 12-Month, Open-Label Study of XXX in Adults with Attention Deficit Hyperactivity Disorder. January 2002 to July 2004.
A Randomized, Double Blind, Placebo-controlled, Parallel-Group Study of XXX in Adults with Attention Deficit Hyperactivity Disorder. January 2002 to September 2002.
A randomized, double-blind, parallel-group, placebo-controlled, study evaluating efficacy and safety of XXX versus placebo in patients with Major Depressive Disorder. September 2001 to July 2002.
A double-blind, randomized, placebo-controlled, 3-month clinical trial of XXX and XXX in the treatment of Posttraumatic Stress Disorder. September 2001 to September 2002.
A randomized, double-blind, placebo-controlled, flexible dosage trial to evaluate the efficacy and tolerability of XXX in patients with Generalized Anxiety Disorder. August 2001 to July 2002.
A double-blind, placebo controlled, fixed-dosage study comparing the efficacy and tolerability of XXX and XXX to placebo in the treatment of Major Depressive Disorder with anxiety. March 2001 to September 2001.
A Six-Week, Double-Blind, Placebo-Controlled Multicenter Study to Evaluate the Safety and Efficacy of 3 Doses of XXX and XXX in Subjects with Major Depression. June 2000 to January 2001.
Open-Label Combination of XXX and XXX in Major Depressive Disorder. February 2000 to June 2002.
A Phase III, Open-Label, Treatment-Switching Study from Orally Administered Antipsychotic Monotherapy to Orally Administered XXX Monotherapy in the Treatment of Chronic Schizophrenia and Schizoaffective Patients. November 1999-July 2000.
XXX Versus Placebo in the Prevention of Relapse in Bipolar Disorder. July 1999-March 2002.
A 12-Week, Randomized, Double-blind, Placebo Controlled, Flexible Dose Study of XXX in the Treatment of Generalized Social Anxiety Disorder. August 1999-February 2000.
A Multicenter, Open-Label, Long-Term, Safety and Efficacy Study of XXX Tablets Once Daily in Subjects With Schizophrenia or Other Psychotic Disorders. September 1998-September 1999.
A 12 week, Double-blind, Placebo controlled, parallel group study to assess the efficacy and tolerability of XXX in Patients suffering from Posttraumatic Stress Disorder (PSTD). January 1999-February 2000.
XXX Verses Placebo in the Treatment of Bipolar Disorder, Manic or Mixed. Eli Lilly. January 1998-November 1998.
XXX Experience with Safety and Tolerability (Quest). Zeneca Limited. August 1997-March 1998.
Sub-investigator:
XXX in Treatment of Schizophrenia, Schizoaffective, and Bipolar Disorder.
Zeneca Limited. February 1997-July 1997.
XXX vs. XXX vs. Placebo in Inpatient Treatment of Melancholic Depression.
Wyeth-Ayerst Laboratories. February 1997-July 1997.
Double-Blind Dose Comparison of IM XXX in Psychosis with Acute Agitation.
Pfizer Pharmaceuticals. January 1997- July 1997.
Additional Research Experience:
McLean Hospital, Consolidated Department of Psychiatry, Harvard Medical School, Belmont, MA. 1992-1994.
Clozapine in Acute Mania - Prospective study to evaluate the safety and efficacy of clozapine in the treatment of refractory acute bipolar mania and psychotic features.
First Psychosis Project - Prospective study to determine characteristics, outcome and response to treatment of all first hospitalized psychotic patients.
Meta-analysis of Clozapine in the Treatment of Acute Psychosis - Literature review analysis of double-blind studies comparing clozapine to typical neuroleptics.
PRESENTATIONS
NCDEU Poster Presentation - Antidepressant Activity of PRX-00023, a Novel, Selective Serotonin 1A Receptor Agonist, in Patients with GAD: Results of a Double Blind, Placebo Controlled Study. Karl Rickels, Sanjay Matthew, Michael Banov, Daniel Zimbroff, et al. June 13, 2007.
New Developments in Psychopharmacology. Professional Education Series. Ridgeview Institute. June 17th and July 20th 2007.
Psychiatry for the Non-Psychiatrist. Georgia Academy of Family Physicians. 52nd Annual Scientific Assembly and Exhibition. November 3, 2000
New Developments in Wakefulness Medications. Continuing Medical Education Series. Summit Ridge Hospital. Lawrenceville, Georgia. October 19, 2000
New Medications for Mental Illness. NAMI-GA Convention. October 14, 2000
Managing Social Anxiety Disorder. Atlanta Steeplechase. SmithKline Beecham. April 15, 2000.
Zyprexa Approved For Treatment of Acute Mania. WSB-TV Interview. Atlanta GA, April 5, 2000
Anticonvulsants in the Management of Bipolar Disorder. Abbott Laboratories. Phillips Arena. Atlanta GA, November 15 1999.
Anxiety Disorders. WSTR-FM. “Steve and Vickie in the Morning”. Atlanta, GA, October 6, 1999
Social Anxiety Disorder. WXIA-TV (NBC). Atlanta GA, October 5, 1999
New Options For Managing Social Anxiety Disorder. WSB-AM (CNN Radio). Atlanta GA, October 5, 1999
New Directions in the Treatment of Bipolar Disorder. Continuing Medical Education Series. Ridgeview Institute. March 3, 1999
Community Discussion About Obsessive-Compulsive Disorder with Marc Summers. Westin Atlanta North at Perimeter. February 25, 1999.
Treatment Issues in Violent Mentally Ill Patients. Clayton County Mental Health Center. Morganton NC, April 20, 1998.
New Advances in Psychopharmacology. Student Assistance Professionals Association, Atlanta, GA, February 18,1998.
Hypochondriasis. WGNX-TV 46 News. September 1997.
The Dangers of Huffing. WGNX-TV 46 News. August 1997.
Assessment and Treatment Strategies in Working with the Patient with Attention Deficit Hyperactivity Disorder. Medical Association of Georgia, Scientific Assembly, Atlanta, GA. November 17, 1995.
Recent Developments in Psychopharmacology. Ridgeview Institute CME Tape Learning Series. October, 1995.
Medicines in Psychiatry. WSB Radio 750. August 1995.
Diagnosing and Treating ADHD in Adults. Ridgeview Institute, Seminars for Clinicians, Atlanta, GA. April 28, 1995.
Seasonal Affective Disorder. Ridgeview Institute, Family Learning Series, Atlanta, GA. January 26, 1995.
Is Clozapine Monotherapy an Effective Mood Stabilizer? Presented at American College of Neuropsychopharmacology, Honolulu, Hawaii, December 17, 1993.
Clozapine Therapy in Refractory Affective Disorders: Polarity Predicts Response in Long-Term Follow-Up. Presented at the American Psychiatric Association Annual Meeting, San Francisco, CA, May 24, 1993.
Clozapine in Affective Disorders. Psychopharmacology Series, Affective Disorders Program, McLean Hospital, May 6, 1993.
Successful Use of Clozapine in Refractory Psychosis with Co-morbid Substance Abuse: A Long Term Follow-Up Study. Harvard Medical School Consolidated Department of Psychiatry Research Day, April 21, 1993.
Clozapine as Maintenance Therapy in Affective Illnesses. Presented at The Boston Society of Neurology and Psychiatry, Cobb Assembly, March 25, 1993.
Obsessive/Compulsive Symptoms in Psychotic Patients: Related or Distinct Entities? Banov MD, Moderator, Clinical Case Conference. McLean Hospital Department of Postgraduate and Continuing Medical Education, January 19, 1993.
CONFERENCES
Sachs GS, Stoll AL, Lafer B, Banov M, Thibeault A, Tohen M, Falk W, Zornberg G, Rosenbaum J, Cohen BM. Bupropion versus Desipramine in Bipolar Depression. Double-blind comparison of acute and maintenance effects. Presented at the Second International Conference on Refractory Depression, Amsterdam, The Netherlands, June 24-26, 1992.
PROFESSIONAL AFFILIATIONS
American Psychiatric Association - 1990 to present
Georgia Psychiatric Association 1994 to present
Massachusetts Psychiatric Association - 1990 to 1994
American Medical Association - 1989 to present
REFERENCES
Available on request.
|
